Ocugen Reports Positive Phase 2 Results for OCU410 in Geographic Atrophy, Stock Down 12.89%

Ocugen reported 12-month Phase 2 data for OCU410, a novel gene therapy for geographic atrophy secondary to dry age-related macular degeneration. The trial met its primary endpoint, with a 31% reduction in GA lesion growth versus control. No serious adverse events were reported. The company plans to initiate a Phase 3 registrational trial in Q3 2026.